Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
19 hedge funds and large institutions have $7.74M invested in Oncternal Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
12% more funds holding
Funds holding: 17 → 19 (+2)
7% more capital invested
Capital invested by funds: $7.22M → $7.74M (+$522K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$102K |
| 2 |
KLI
Kelman-Lazarov Inc
Memphis,
Tennessee
|
+$73K |
| 3 |
BlackRock
New York
|
+$48.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$11K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$305K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$28.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.59K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$2K |
ONCT Hedge Fund Activity: Q2 2017 in Review
19 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2017, worth a combined $7.74M — up 7.2% from $7.22M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ONCT positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $102K. The largest seller was Millennium Management, exiting entirely with an estimated $305K sold.
- 19 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2017, up from 17 in Q1 2017.
- Funds reported $7.74M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2017, up 7.2% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2017 was Bank of New York Mellon, an estimated $102K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2017 was Millennium Management, an estimated $305K sold.
Based on aggregated 13F filings for Q2 2017.